Relationship of serum markers of cartilage metabolism to imaging and clinical outcome measures of knee joint structure
- 15 June 2010
- journal article
- research article
- Published by BMJ in Annals Of The Rheumatic Diseases
- Vol. 69 (10), 1816-1822
- https://doi.org/10.1136/ard.2009.124420
Abstract
Background Biomarkers of cartilage metabolism have prognostic potential. Objective To examine whether serum cartilage biomarkers, cartilage oligomeric matrix protein (COMP), N-propeptide of type IIA procollagen (PIIANP), type II collagen breakdown product (collagen type-II cleavage (C2C)) predict cartilage volume loss and knee joint replacement. Methods 117 subjects with knee osteoarthritis (OA) had MRI at baseline and 2 years. Cartilage biomarkers were measured at baseline. Change in knee cartilage volume over 2 years and knee joint replacement over 4 years was determined. The population was divided into subgroups with high or low cartilage biomarkers (based on biomarker levels greater than or equal to, or less than, the mean, respectively). The relationships between biomarkers and outcome measures were examined in the whole population, and separately in marker subgroups. Results The relationship between cartilage biomarkers and cartilage volume loss was not linear across the whole population. In the low (regression coefficient B=-9.7, 95% CI -0.01 to 0.003, p=0.01), but not high (B=-0.46, 95% CI -8.9 to 8.0, p=0.92) COMP subgroup, COMP was significantly associated with a reduced rate of medial cartilage volume loss (p for difference between groups=0.05). Similarly, in the low (B=-8.2, 95% CI -12.9 to -3.5, p=0.001) but not high (B=2.6, 95% CI -3.3 to 8.5, p=0.38) PIIANP subgroup, PIIANP was associated with a significantly reduced rate of medial volume cartilage loss (p for difference=0.003). C2C was not significantly associated with rate of cartilage volume loss. PIIANP was associated with a reduced risk of joint replacement (odds ratio (OR)=0.28, 95% CI 0.10 to 0.93, p=0.04). Conclusion Cartilage biomarkers may be used to identify subgroups among those with clinical knee OA in whom disease progresses at different rates. This may facilitate our understanding of the pathogenesis of disease and allow us to differentiate phenotypes of disease within a heterogeneous knee OA population.This publication has 21 references indexed in Scilit:
- Can biochemical markers serve as surrogates for imaging in knee osteoarthritis?Arthritis & Rheumatism, 2007
- The ratio of type II collagen breakdown to synthesis and its relationship with the progression of knee osteoarthritisOsteoarthritis and Cartilage, 2007
- Association of higher levels of serum cartilage oligomeric matrix protein and N‐telopeptide crosslinks with the development of radiographic hip osteoarthritis in elderly womenArthritis & Rheumatism, 2005
- The assessment of cartilage degradation in vivo: development of an immunoassay for the measurement in body fluids of type II collagen cleaved by collagenasesJournal of Immunological Methods, 2004
- Suggestion of nonlinear or phasic progression of knee osteoarthritis based on measurements of serum cartilage oligomeric matrix protein levels over five yearsArthritis & Rheumatism, 2004
- Serum levels of type IIA procollagen amino terminal propeptide (PIIANP) are decreased in patients with knee osteoarthritis and rheumatoid arthritis.Osteoarthritis and Cartilage, 2004
- Identification of cartilage oligomeric matrix protein (COMP) gene mutations in patients with pseudoachondroplasia and multiple epiphyseal dysplasiaJournal of Human Genetics, 2003
- Comparison of tibial cartilage volume and radiologic grade of the tibiofemoral jointArthritis & Rheumatism, 2003
- Uncoupling of type II collagen synthesis and degradation predicts progression of joint damage in patients with knee osteoarthritisArthritis & Rheumatism, 2002
- The determinants of change in tibial cartilage volume in osteoarthritic kneesArthritis & Rheumatism, 2002